Clinical Trials Logo

Clinical Trial Summary

The study assessed the efficacy of a methadone-induced memory retrieval-extinction procedure on heroin craving and relapse. Male participants aged 18-55 years old and prescribed MMT to treat heroin dependence were included in the present study, and randomly assigned to receive methadone, or receive methadone plus 10 minutes plus extinction, or receive methadone plus 6 hours plus extinction. The intervention persisted 3 times per week for 4 weeks. Then the subjects were followed up once a month for cue induced heroin craving and relapse.


Clinical Trial Description

In the present study, we explored the effect retrieval-extinction procedure on heroin craving and relapse in heroin addicts using the methadone (a commonly used µ-opioid receptor agonist) instead of heroin as the trigger to reactivate drug memories. The subjects were randomly divided into 3 groups, in which they received methadone alone or extinction sessions 10 min or 6 hours after methadone administration. The extinction sessions were given 3 times per week for 4 weeks, each lasted for 30 min. During the extinction procedure, the subjects were exposed to images, heroin paraphernalia and mimic heroin. Subjective craving, morphine urine test and physiological responses were recorded monthly for 4 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04133974
Study type Interventional
Source National Institute on Drug Dependence, China
Contact
Status Completed
Phase N/A
Start date November 20, 2015
Completion date April 20, 2019

See also
  Status Clinical Trial Phase
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00218309 - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals Phase 2
Completed NCT00000210 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Phase 2
Completed NCT00000211 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Phase 2
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Withdrawn NCT00000330 - Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Phase 2
Completed NCT00249457 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2 N/A
Completed NCT00218127 - Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Phase 2
Completed NCT00015288 - Buprenorphine and Naloxone Combination Study - 10 Phase 1
Terminated NCT03711318 - Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals Phase 3
Recruiting NCT02541526 - Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Phase 3
Active, not recruiting NCT02541513 - An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Phase 3
Completed NCT01760473 - Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Phase 3
Terminated NCT01395797 - Pioglitazone for Heroin and for Nicotine Dependence Phase 1/Phase 2
Completed NCT01668706 - Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2
Completed NCT00684840 - Effects of Stress and Other Factors on Opiate Drug Choice. N/A
Completed NCT00759005 - Effect of Stress on Heroin-Related Memory Retrieval N/A
Completed NCT00218530 - Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Phase 1
Completed NCT00158288 - The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Phase 2